Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

allogeneic gamma-delta T lymphocytes TCB-008

A preparation of ex vivo-expanded, allogeneic T lymphocytes that express only gamma chain and delta chain T-cell receptors (TCRs), with potential immunomodulating and antineoplastic activities. Upon administration of the allogeneic gamma-delta T lymphocytes TCB-008, these cells secrete interferon-gamma (IFN-g) and exert direct killing of tumor cells. In addition, these cells activate the immune system to exert a cytotoxic T-lymphocyte (CTL) response against tumor cells. Gamma-delta T lymphocytes play a key role in the activation of the immune system and do not require major histocompatibility complex (MHC)-mediated antigen presentation to exert their cytotoxic effect.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:allogeneic famma-delta T lymphocytes TCB-008
allogeneic gamma-delta T cells TCB-008
Code name:TCB 008
TCB-008
TCB008
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search